LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other providers; and iNR Wellness MD, a supplement for immune and digestive support. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: lifemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $12.00 | Buy | Lake Street |
| 12/4/2024 | $7.00 | Neutral | Mizuho |
| 8/23/2024 | $11.00 | Buy | B. Riley Securities |
| 6/5/2024 | $12.00 | Overweight | KeyBanc Capital Markets |
| 11/30/2023 | $10.00 | Buy | Craig Hallum |
| 7/21/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/3/2023 | $9.00 | Buy | H.C. Wainwright |
| 3/10/2022 | $14.00 | Buy | Colliers Securities |
| 10/4/2021 | $16.00 | Buy | B. Riley Securities |
10-Q - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
DEFA14A - LifeMD, Inc. (0000948320) (Filer)
DEF 14A - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
10-K - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
S-8 - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended March 31, 2025 on Monday, April 28, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on April 28, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https:
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2025, to holders of record at the close of business on April 4, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's h
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on March 10, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 10thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy servi
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of $0.07 (non-GAAP adjusted EPS of $0.10) Cash, Cash Equivalents, and Investment Securities of $162.3 million and no debt Full Year 2024 Revenue of $602.5 million Net income of $2.1 million (non-GAAP adjusted net i
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 18, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.Medif
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2025, to holders of record at the close of business on January 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women'
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
SC 13D - LifeMD, Inc. (0000948320) (Subject)
SC 13D/A - LifeMD, Inc. (0000948320) (Subject)
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's a
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.B. Riley Securities 25th Annual Institutional Investor Conference, May 21-22 at the Ritz-Carlton in Marina Del Rey. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.Craig-Hallum 22nd Annual Institutional Investor Conference, May 28 at The Depo
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform. LifeMD's weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single,
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states anticipated by the end of the second quarter. "We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight manag
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended March 31, 2025 on Monday, April 28, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on April 28, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https:
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertical
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2025, to holders of record at the close of business on April 4, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's h
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00
Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00
KeyBanc Capital Markets initiated coverage of LifeMD with a rating of Overweight and set a new price target of $12.00
Craig Hallum initiated coverage of LifeMD with a rating of Buy and set a new price target of $10.00
Cantor Fitzgerald initiated coverage of LifeMD with a rating of Overweight and set a new price target of $7.00
H.C. Wainwright initiated coverage of LifeMD with a rating of Buy and set a new price target of $9.00
Colliers Securities initiated coverage of LifeMD with a rating of Buy and set a new price target of $14.00
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $16.00
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec
NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere's appointment, LifeMD's Board will comprise nine directors, seven of whom are independent. "We are pleased to welcome Dr. LaRovere to the LifeMD Board," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Dr. LaRovere's leadership and clinical experience at two of the top hospitals in the world, combined with her deep background in healthcare data, analytics, machine learning, and artificial intelligence will be invaluable to LifeMD as we grow our bus
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Jessica Friedeman as Chief Marketing Officer. Friedeman succeeds Stefan Galluppi, who continues as LifeMD's Chief Innovation Officer. Friedeman brings nearly twenty years' experience engaging and retaining patients, with a proven track record of increasing efficiency and revenue by executing go-to-market product strategy for forward-thinking, high growth companies. She offers specialized knowledge in customer relationship management, SaaS technology, and the application of actionable insights through data science. Friedeman has
NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, is pleased to announce its appointment of Bobby Jindal, the 55th Governor of the State of Louisiana, to its board of directors. Mr. Jindal was elected as the nation's youngest governor in 2007 and spent two terms as Louisiana's chief executive officer to rebuild and diversify the state's economy and financial footing in the aftermath of Hurricanes Katrina and Rita. Prior to serving as Governor, Mr. Jindal held positions as the head of the Louisiana Department of Health and Hospitals, President of the University of Louisiana System, Assistant Secretary of the U.S. Depart
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced its appointment of Naveen Bhatia to its board of directors. Mr. Bhatia is a private investor and has served as a director of numerous public and private companies; currently, he serves on the Board of Directors of Blue Yonder, EquipmentShare, RG Barry, and CRG Financial. He also previously served as the Chairman of the Board of Cotton Holdings from 2010-2019. From 2013 to 2020, Mr. Bhatia was a Senior Director in the Tactical Opportunities group of Blackstone, involved with sourcing, evaluating, and executing investment opportunities. "We are ex
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. ("the Company") (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of prominent dermatologist and surgeon, Dr. Matthew Zipoli, as a medical advisor for tele-dermatology brand Nava MD. Dr. Zipoli will collaborate with the Company to further enhance the brand's development goals. With over two decades of experience, Dr. Zipoli is a leading specialist in Mohs Surgery for the treatment of skin cancers. He is affiliated with Mount Auburn and Emerson Hospitals in the greater-Boston area, and serves as a Clinical Instructor at Tufts University School of Medicine. Dr. Zipoli graduated from Boston U
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and full year ended December 31, 2020. All quarterly and full year comparisons are to the same year-ago period. The company will hold a conference call at 4:30 p.m. Eastern time today to discuss the results (see dial-in information below.) Q4 Financial Highlights Revenue increased 227% to a record $12.9 million.82% of Q4 2020 revenue was generated by subscriptions, up from 48% in Q4 2019.Telemedicine net orders increased 275% to more than 117,000.Annual recurring revenue (ARR) from subscriptions at December 31, 2020 reached $53